DOCSLIB.ORG

Nutritional and Herbal Therapies for Children and Adolescents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nutritional and Herbal Therapies for Children and Adolescents Nutritional and Herbal Therapies for Children and Adolescents A Handbook for Mental Health Clinicians Nutritional and Herbal Therapies for Children and Adolescents A Handbook for Mental Health Clinicians George M. Kapalka Associate Professor, Monmouth University West Long Branch, NJ and Director, Center for Behavior Modifi cation Brick, NJ AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA Copyright © 2010 Elsevier Inc. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (44) (0) 1865 843830; fax (44) (0) 1865 853333; email: [email protected]. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress ISBN : 978-0-12-374927-7 For information on all Academic Press publications visit our website at www.elsevierdirect.com Typeset by Macmillan Publishing Solutions www.macmillansolutions.com Printed and bound in the United States of America 10 11 12 13 14 15 10 9 8 7 6 5 4 3 2 1 Preface Many years ago, when symptoms of most psychological disorders were just beginning to be identified, the prevailing belief was that these symp- toms were the result of deeply embedded psychogenic conflicts that required psychoanalysis to work through. Over the past five decades, however, a plethora of research revealed that many individuals with these disorders exhibit structural and functional differences in their brains. According to our current knowledge of the neuropsychiatric aspects of psychological disorders, attention deficit hyperactivity disorder (ADHD), Tourette’s disorder, obsessive compulsive disorder (OCD), panic disor- der, depression, bipolar disorder, and schizophrenia are characterized by significant changes in the brain. Moreover, the earlier the onset of the symptoms, the more significant those brain differences appear to be. Since brain changes are likely to be reflected in feelings and behav- iors, psychopharmacological approaches were developed to try to address some of the biological factors that may be responsible, at least in part, for the symptoms. Indeed, many of these have proven effective in reducing (and, sometimes, eliminating) the symptoms of some psy- chological disorders, and intervening pharmacologically may be ben- eficial, and in some cases is indispensable, since without medications some symptoms (for example, psychosis) are not likely to resolve. As advances in psychopharmacology continued, a biopsychosocial approach developed and aimed to conceptualize effective mental health treatment as falling across three dimensions – biological (use of medica- tions), psychological (counseling and psychotherapy), and social (group and family counseling, development of social supports). Over time, med- icine (especially, psychiatry) began to favor the biological aspects and pharmacological interventions. However, the biopsychosocial approach was developed to balance the three aspects of mental health care, and many mental health professionals continue to approach psychological care from the biopsychosocial perspective, utilizing pharmacological approaches in conjunction with psychosocial treatment, especially when treating individuals with disorders that are known to be associated with significant changes in the brain. ix x Preface BIOLOGICAL VS. PSYCHOSOCIAL TREATMENT When treating disorders with known biological etiology, many non- medical mental health professionals seek to minimize pharmacological approaches and initially try psychosocial treatment. This is a reasonable approach, especially with children. However, many factors may contrib- ute to the decision to utilize pharmacological approaches, in conjunc- tion with or instead of psychotherapy. Type of Symptoms Some symptoms may lend themselves well to psychotherapy. For exam- ple, depression or generalized anxiety generally respond well to psy- chosocial treatment, and results of numerous research studies reveal that individuals who undergo psychotherapeutic treatment for such symptoms exhibit statistically significant improvement (for example, see Beck, 1995). Of course, improvement does not necessarily mean the elimination of symptoms, so in many cases conjoint psychopharmaco- logical treatment may offer additional benefits. Conversely, some symptoms do not seem to respond well to psycho- therapy. For example, delusions, hallucinations, racing thoughts, and other symptoms associated with severe psychopathology do not tend to significantly diminish with psychosocial interventions. True, concur- rent psychotherapy may help the patient’s overall adjustment, but the core symptoms are not likely to resolve without the use of at least some pharmacological interventions. Severity of Symptoms Even those symptoms that may often be manageable without medications may sometimes require a pharmacological approach. For example, milder forms of depression, impulsivity, anxiety, or agitation may respond well to psychotherapy. However, severe variants of these symptoms may be diffi- cult to treat with talk therapies, and intense symptoms are likely to require psychopharmacological treatment. For example, it may be very difficult to communicate with a severely depressed or agitated patient, and a severely anxious patient may have difficulties coming in for psychotherapy. Thus, most clinicians find that symptoms that are very impairing usually require an approach that includes pharmacological treatment. Onset of Relief When psychotherapy is effective, progression of improvement is gradual and requires several sessions to become evident. Even those variants that Preface xi are called ‘brief therapy’ generally require 8–15 sessions before signifi- cant improvement is expected. When the patient is very uncomfortable, and when the symptoms debilitate the patient and significantly interfere with normal functioning, waiting this long for improvement may not be prudent. Although this is not always the case, many pharmacological treat- ments produce at least some improvement within days of the onset of treatment, although a few weeks (in some cases, 4–6) may be needed for more comprehensive response. However, this is still faster than psy- chotherapy, and the amount of improvement seen with medications may be greater than the improvement seen with psychotherapy over the same period of time. Especially when symptoms are severe, it may be more appropriate to initiate pharmacological treatment immediately, perhaps conjointly with psychosocial interventions. Relief is likely to be faster when such a strategy is utilized. Time and Effort When pharmacological and non-pharmacological approaches are likely to be equally effective, as is the case with pharmacological or psychothera- peutic treatment of depression, non-medical mental health professionals prefer to utilize non-medical treatments, and pharmacological interven- tions are seen as a ‘last resort’ when therapy does not seem to produce sufficient relief. While this may be reasonable in some situations, pro- fessionals need to be sensitive to other reasons that may drive the use of pharmacological interventions. In order for psychotherapy to be effective, patients need to attend ses- sions regularly. If rapid progress is needed, sessions need to be scheduled at least weekly. However, driving to the therapist’s office once per week, and spending an hour in the office, may be difficult for some patients (or families) with significant time obligations. When the patient is a child or adolescent, psychotherapy must be done outside of school hours, since missing school 1 day per week to attend psychotherapy is neither practical for the family nor beneficial to the student. However, it may be difficult to find therapists with significant amount of evening hours to accommodate the patient’s schedule, especially when weekly treatment is needed. In addition, geographic considerations also affect the decision to enter psychotherapy. In urban or suburban areas, child and adolescent psy- chotherapists may be prevalent. In rural areas, however, this situation is much more likely to be problematic, and patients may not live in reason- able proximity of qualified and competent pediatric mental health pro- fessionals. Thus, even when a family may prefer to try psychotherapy xii Preface instead of pharmacy, their ability to get to the therapist’s
Load more

Recommended publications
  • 4695389.Pdf (3.200Mb)
    Non-classical amine recognition evolved in a large clade of olfactory receptors The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Li, Qian, Yaw Tachie-Baffour, Zhikai Liu, Maude W Baldwin, Andrew C Kruse, and Stephen D Liberles. 2015. “Non-classical amine recognition evolved in a large clade of olfactory receptors.” eLife 4 (1): e10441. doi:10.7554/eLife.10441. http://dx.doi.org/10.7554/ eLife.10441. Published Version doi:10.7554/eLife.10441 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993622 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA RESEARCH ARTICLE Non-classical amine recognition evolved in a large clade of olfactory receptors Qian Li1, Yaw Tachie-Baffour1, Zhikai Liu1, Maude W Baldwin2, Andrew C Kruse3, Stephen D Liberles1* 1Department of Cell Biology, Harvard Medical School, Boston, United States; 2Department of Organismic and Evolutionary Biology, Museum of Comparative Zoology, Harvard University, Cambridge, United States; 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States Abstract Biogenic amines are important signaling molecules, and the structural basis for their recognition by G Protein-Coupled Receptors (GPCRs) is well understood. Amines are also potent odors, with some activating olfactory trace amine-associated receptors (TAARs). Here, we report that teleost TAARs evolved a new way to recognize amines in a non-classical orientation.
    [Show full text]
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • The Breakdown of Pyruvate by Cell-Free Extracts of the Rumen Micro-Organism LC
    Vol. 74 METABOLISM OF XANTHURENIC ACID 525 with acid; no direct proof, however, is given that that the hydroxyl group in position 8 is bound to this transformation is brought about by detach- glucuronic acid. ment of a glucuronic residue from the hydroxyl group in position 4 of xanthurenic acid. The fact The authors are grateful to Professor Benassi of the that the R. values of Rothstein & Greenberg's Institute of Pharmaceutical Chemistry of the University of compounds B and D in butanol-acetic acid-water Padova for a kind gift of a sample of 8-methylxanthurenic (4:1:5) differ from those of our compounds indicate acid ethyl ester. that they are not the same substances. The differ- REFERENCES ence might tentatively be ascribed to the fact that xanthurenic acid can be conjugated in the living Baglioni, C., Fasella, P., Turano, C. & Siliprandi, N. (1960). organism in several ways and that differences exist G. Biochim. (in the Press). not only between various species, e.g. the rabbit Block, R. J. & Boiling, D. (1951). The Aminoacid Compo8i- and the rat (Rothstein & Greenberg, 1957), but tion of Protein and Foods, p. 413. Springfield, Mass.: also between different races of the same C. Thomas. species. Consden, R., Gordon, A. H. & Martin, A. J. P. (1944). Biochem. J. 38, 224. SUMMARY Dalglesh, C. E. (1952). Biochem. J. 52, 3. Dalgliesh, C. E. (1955). J. clin. Path. 8, 73. 1. Two major metabolites of xanthurenic acid Daigliesh, C. E. (1956). Biochem. J. 64, 481. were found in the urine of albino rats after intra- Dent, C.
    [Show full text]
  • Herbal Medicines in Pregnancy and Lactation : an Evidence-Based
    00 Prelims 1410 10/25/05 2:13 PM Page i Herbal Medicines in Pregnancy and Lactation An Evidence-Based Approach Edward Mills DPh MSc (Oxon) Director, Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Jean-Jacques Duguoa MSc (cand.) ND Naturopathic Doctor Toronto Western Hospital Assistant Professor Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Dan Perri BScPharm MD MSc Clinical Pharmacology Fellow University of Toronto Toronto, Ontario, Canada Gideon Koren MD FACMT FRCP Director of Motherisk Professor of Medicine, Pediatrics and Pharmacology University of Toronto Toronto, Ontario, Canada With a contribution from Paul Richard Saunders PhD ND DHANP 00 Prelims 1410 10/25/05 2:13 PM Page ii © 2006 Taylor & Francis Medical, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2006 by Taylor & Francis Medical, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN Tel.: ϩ44 (0)20 7017 6000 Fax.: ϩ44 (0)20 7017 6699 E-mail: [email protected] Website: www.tandf.co.uk/medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or trans- mitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP.
    [Show full text]
  • Learning Alters Theta-Nested Gamma Oscillations in Inferotemporal Cortex
    Learning alters theta-nested gamma oscillations in inferotemporal cortex Keith M Kendrick1, Yang Zhan1, Hanno Fischer1 Ali U Nicol1 Xuejuan Zhang 2 & Jianfeng Feng3 1Cognitive and Behavioural Neuroscience, The Babraham Institute, Cambridge, CB22 3AT, UK 2Mathematics Department, Zhejiang Normal University, Jinhua 321004, Zhejian Province, PR China 3Department of Computer Science, Warwick University, Coventry CV4 7AL UK and Centre for Computational Systems Biology, Fudan University, Shanghai, PR China. Corresponding authors: [email protected] [email protected] 1 How coupled brain rhythms influence cortical information processing to support learning is unresolved. Local field potential and neuronal activity recordings from 64- electrode arrays in sheep inferotemporal cortex showed that visual discrimination learning increased the amplitude of theta oscillations during stimulus presentation. Coupling between theta and gamma oscillations, the theta/gamma ratio and the regularity of theta phase were also increased, but not neuronal firing rates. A neural network model with fast and slow inhibitory interneurons was developed which generated theta nested gamma. By increasing N-methyl-D-aspartate receptor sensitivity similar learning-evoked changes could be produced. The model revealed that altered theta nested gamma could potentiate downstream neuron responses by temporal desynchronization of excitatory neuron output independent of changes in overall firing frequency. This learning-associated desynchronization was also exhibited by inferotemporal cortex neurons. Changes in theta nested gamma may therefore facilitate learning-associated potentiation by temporal modulation of neuronal firing. The functions of both low and high frequency oscillations in the brain have been the subject of considerable speculation1. Low frequency theta oscillations (4-8Hz) have been observed to increase in terms of power and phase-locked discharge of single neurons in a visual memory task2.
    [Show full text]
  • Measuring Sleep Quality from EEG with Machine Learning Approaches
    Measuring Sleep Quality from EEG with Machine Learning Approaches Li-Li Wang, Wei-Long Zheng, Hai-Wei Ma, and Bao-Liang Lu∗ Center for Brain-like Computing and Machine Intelligence Department of Computer Science and Engineering Key Laboratory of Shanghai Education Commission for Intelligent Interaction and Cognitive Engineering Brain Science and Technology Research Center Shanghai Jiao Tong University, Shanghai, 200240, China Abstract—This study aims at measuring last-night sleep quality Index [2], Epworth Sleep Scale [3], and Sleep Diaries [4]. from electroencephalography (EEG). We design a sleep ex- However, we have no way of knowing whether the respondents periment to collect waking EEG signals from eight subjects are honest, conscientious, responsible for self assessment and under three different sleep conditions: 8 hours sleep, 6 hours sleep, and 4 hours sleep. We utilize three machine learning related records and in many cases they may provide false approaches, k-Nearest Neighbor (kNN), support vector machine information or fill in the questionnaire not seriously. Secondly, (SVM), and discriminative graph regularized extreme learning the subjective evaluation method is more troublesome, time- machine (GELM), to classify extracted EEG features of power consuming and laborious, which requires participants to se- spectral density (PSD). The accuracies of these three classi- riously think about, a detailed answer, record relevant infor- fiers without feature selection are 36.68%, 48.28%, 62.16%, respectively. By using minimal-redundancy-maximal-relevance mation in time, in the meantime, experiment personnel also (MRMR) algorithm and the brain topography, the classification need a manual investigation and analysis of the information accuracy of GELM with 9 features is improved largely and in order to give a sleep quality evaluation and judgment of increased to 83.57% in average.
    [Show full text]
  • Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence
    CNS Drugs 2013; 24 (5) Review Article Running Header: Plant-Based Anxiolytic Psychopharmacology Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence Jerome Sarris,1,2 Erica McIntyre3 and David A. Camfield2 1 Department of Psychiatry, Faculty of Medicine, University of Melbourne, Richmond, VIC, Australia 2 The Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia 3 School of Psychology, Charles Sturt University, Wagga Wagga, NSW, Australia Correspondence: Jerome Sarris, Department of Psychiatry and The Melbourne Clinic, University of Melbourne, 2 Salisbury Street, Richmond, VIC 3121, Australia. Email: [email protected], Acknowledgements Dr Jerome Sarris is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, The Centre for Human Psychopharmacology at the Swinburne University of Technology. Jerome Sarris, Erica McIntyre and David A. Camfield have no conflicts of interest that are directly relevant to the content of this article. 1 Abstract Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical evidence of anxiolytic activity. We present the article in two parts. In part one, we reviewed herbal medicines for which only preclinical investigations for anxiolytic activity have been performed. In this current article (part two), we review herbal medicines for which there have been both preclinical and clinical investigations for anxiolytic activity.
    [Show full text]
  • Neurotransmitters-Sample-Report
    Neurotransmitters Test the messengers of your neural network 1(866) 364-0963 www.vibrant-wellness.com 1360 Bayport Ave. Ste. B [email protected] San Carlos, CA 94070 Neurotransmitters Vibrant Wellness | 1360 Bayport Ave, Ste B. San Carlos, CA 94070 1(866) 364-0963 | [email protected] | www. vibrant-wellness.com Final Report Date: 06-19-2020 16:03 Specimen Collected: 06-18-2020 16:03 Accession ID: 2006190275 Specimen Received: 06-19-2020 10:03 LAST NAME FIRST NAME GENDER DATE OF BIRTH ACCESSION ID DATE OF SERVICE PATIENT TEST2 MALE 1998-01-06 2006190275 06-18-2020 16:03 PATIENT PROVIDER Name: TEST2 PATIENT Practice Name: Vibrant IT4 Practice Date of Birth: 1998-01-06 Provider Name: Demo Client, DDD (999994) Gender: Male Street Address: TEST STREET Age: 22 City: TEST CITY State: KY Fasting: FASTING Zip #: 42437 Telephone #: Fax #: 000-000-0000 Vibrant Wellness is pleased to present to you, 'Neurotransmitters', to help you make healthy lifestyle, dietary and treatment choices in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being. The Vibrant Neurotransmitters is a test to measure inhibitory, excitatory and other neurotransmitters . The panel is designed to give a complete picture of an individual’s levels of neurotransmitters in urine. Interpretation of Report: The report contains the complete list of the all urine neurotransmitters tested with quantitative results to enable a full overview along with the corresponding reference ranges. The classification of Red indicates a result that is outside the reference range and the classification of Green denotes a result that is within the reference range.
    [Show full text]
  • Amino Acids Amino Acids
    Amino Acids Amino Acids What Are Amino Acids? Essential Amino Acids Non Essential Amino Acids Amino acids are the building blocks of proteins; proteins are made of amino acids. Isoleucine Arginine (conditional) When you ingest a protein your body breaks it down into the individual aminos, Leucine Glutamine (conditional) reorders them, re-folds them, and turns them into whatever is needed by the body at Lysine Tyrosine (conditional) that time. From only 20 amino acids, the body is able to make thousands of unique proteins with different functions. Methionine Cysteine (conditional) Phenylalanine Glycine (conditional) Threonine Proline (conditional) Did You Know? Tryptophan Serine (conditional) Valine Ornithine (conditional) There are 20 different types of amino acids that can be combined to make a protein. Each protein consists of 50 to 2,000 amino acids that are connected together in a specific Histidine* Alanine sequence. The sequence of the amino acids determines each protein’s unique structure Asparagine and its specific function in the body. Asparate Popular Amino Acid Supplements How Do They Benefit Our Health? Acetyl L- Carnitine: As part of its role in supporting L-Lysine: L-Lysine, an essential amino acid, is mental function, Acetyl L-Carnitine may help needed to support proper growth and bone Proteins (amino acids) are needed by your body to maintain muscles, bones, blood, as support memory, attention span and mental development. It can also support immune function. well as create enzymes, neurotransmitters and antibodies, as well as transport and performance. store molecules. N-Acetyl Cysteine: N-Acetyl Cysteine (NAC) is a L-Arginine: L-Arginine is a nonessential amino acid form of the amino acid cysteine.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0314884 A1 Cheyene (43) Pub
    US 20140314884A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0314884 A1 Cheyene (43) Pub. Date: Oct. 23, 2014 (54) HEALTH SUPPLEMENT USING GUARANA A61E36/53 (2006.01) EXTRACT A613 L/455 (2006.01) (52) U.S. Cl. (71) Applicant: Shaahin Cheyene, Venice, CA (US) CPC ............... A61K 36/534 (2013.01); A61K 36/53 (2013.01); A61K 36/16 (2013.01); A61K 36/41 (72) Inventor: Shaahin Cheyene, Venice, CA (US) (2013.01); A6 IK3I/522 (2013.01); A61 K 3I/714 (2013.01); A61 K3I/455 (2013.01); (21) Appl. No.: 13/751,151 A6 IK3I/221 (2013.01); A61 K3I/685 (2013.01); A61 K3I/198 (2013.01); A61 K (22) Filed: Apr. 17, 2013 31/4375 (2013.01); A61K 31/439 (2013.01): A6 IK3I/05 (2013.01) Publication Classification USPC .......................................................... 424/745 (51) Int. Cl. (57) ABSTRACT A6 IK36/534 (2006.01) The current invention is a Supplement made from a combina A6 IK 36/6 (2006.01) tion of herbs, vitamins, amino acids which in the preferred A6 IK 36/4I (2006.01) embodiment is a 100% vegetarian liquid capsules that are A6 IK3I/522 (2006.01) ingested allow for rapid absorption. The components of the A6 IK3I/714 (2006.01) Supplement can be mint or menthol Such as peppermint or A6 IK3I/05 (2006.01) spearmint, Methyl B12 or B12, Niacin, Guarana, Dimethy A6 IK3I/22 (2006.01) laminoethanol, Acetyl-L-carnitine or ALCAR, Ocimum A6 IK3I/685 (2006.01) tenuiflorum, one or more teas Such as green tea, white tea or A6 IK3I/98 (2006.01) black tea, Ginkgo, Rhodiola rosea, phosphatidylserine, A6 IK3I/4375 (2006.01) Tyrosine, L-Alpha Glycerylphosphorylcholine, Citicoline A6 IK3I/439 (2006.01) (INN), Huperzine A, and Vinpocetine.
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]
  • Gamma-Aminobutyric Acid (GABA) Is a Major Neuro­Transmitter Widely Distributed Throughout the Central Nervous System (CNS)
    Alternative Medicine Review Volume 12, Number 3 2007 Monograph GABA Gamma-Aminobutyric O + Acid (GABA) H3N O- Introduction Gamma-aminobutyric acid (GABA) is a major neuro transmitter widely distributed throughout the central nervous system (CNS). Because too much excitation can lead to irritability, restlessness, insomnia, seizures, and movement disorders, it must be balanced with inhibition. GABA – the most important inhibitory neurotransmitter in the brain – provides this inhibition, acting like a “brake” during times of runaway stress. Medications for anxiety, such as benzodiazepines, stimulate GABA receptors and induce relaxation. Either low GABA levels or decreased GABA function in the brain is associated with several psy- chiatric and neurological disorders, including anxiety, depression, insomnia, and epilepsy. Studies indicate GABA can improve relaxation and enhance sleep. Both synthetic and natural GABA are available as dietary supplements in the United States. Natural GABA is produced via a fermentation process that utilizes Lactobacillus hilgardii – the bacteria used to ferment vegetables in the preparation of the traditional Korean dish known as kimchi. Biochemistry and Pharmacokinetics Within the brain, glutamic acid is converted to GABA via the enzyme glutamate decarboxylase and its cofac- tor pyridoxal 5’ phosphate (P5P; active vitamin B6). GABA is metabolized by gamma-aminobutyrate transaminase, also a P5P-dependent enzyme, forming an intermediate metabolite succinate semialdehyde. This metabolite can then be reduced to gamma-hydroxybutyrate, or oxidized to succinate and eventually converted to CO2 and water via the citric acid cycle. When plasma membrane depolarization induces the release of GABA from nerve terminals, GABA binds to GABA receptors – such as the GABAA and GABAB receptors – that are distributed on post-synaptic cell membranes.
    [Show full text]